First biosimilar approved for macular degeneration, other eye conditions

First biosimilar approved for macular degeneration, other eye conditions

(HealthDay)—The first biosimilar to Lucentis (ranibizumab injection) has been approved for the treatment of neovascular (wet) age-related macular degeneration and other eye diseases and conditions, the U.S. Food and Drug Administration announced Friday.

The approval of the biosimilar, Byooviz (ranibizumab-nuna), is also indicated to treat macular edema after and myopic choroidal neovascularization. Byooviz is administered monthly through intravitreal injection.

Approval was based on a data review that included "extensive structural and functional characterization, comparative clinical efficacy and , including potential immunogenicity that demonstrated Byooviz is biosimilar to Lucentis," the FDA wrote in a press release.

Potential serious side effects caused by Byooviz administration include endophthalmitis and retinal detachments, increased intraocular pressure, and thromboembolic events. The most commonly reported side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular fluid pressure.

The FDA has so far approved 31 biosimilars for the treatment of various health conditions. "Continuing to grow the number of biosimilar approvals is a key part of our efforts to provide greater access to for patients, increase competition and potentially lower costs," Sarah Yim, M.D., director of the Office of Therapeutic Biologics and Biosimilars in the FDA Center for Drug Evaluation and Research, said in the press release.


Explore further

Lucentis approved for diabetic retinopathy

More information: More Information

Copyright © 2021 HealthDay. All rights reserved.

Citation: First biosimilar approved for macular degeneration, other eye conditions (2021, September 24) retrieved 4 October 2022 from https://medicalxpress.com/news/2021-09-biosimilar-macular-degeneration-eye-conditions.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
11 shares

Feedback to editors